Başer, Onur

Profile URL
https://hdl.handle.net/20.500.11779/2820
Name Variants
Job Title
Email Address
basero@mef.edu.tr
Main Affiliation
04. Faculty of Economics, Administrative and Social Sciences
Status
Former Staff
Website
ORCID ID
0000-0001-7447-5672
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
JUE-8293-2023
No research topics data found.

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
44
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
10
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
2
Research Products
This researcher does not have a Scopus ID.
Documents

0

Citations

0

Go to WoS profile
No records found in other affiliations.
Scholarly Output

96

Articles

27

Views / Downloads

17858/94440

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

399

Scopus Citation Count

440

Patents

0

Projects

0

WoS Citations per Publication

4.16

Scopus Citations per Publication

4.58

Open Access Source

22

Supervised Theses

0

JournalCount
Value in Health31
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting.18
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress5
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting4
American Heart Association (AHA) Scientific Sessions 20152
Current Page: 1 / 8

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2014 - 2019932020 - 20213

Settings

Author of Publication: search.filters.isAuthorOfPublication.6960b0ec-7a84-4e87-a091-3b9e22c72a9c

Scholarly Output Search Results

Now showing 1 - 10 of 96
  • Conference Object
    Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population
    (2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur
    ...
  • Conference Object
  • Conference Object
    Spatial Distribution of the Total Number of Medical Devices in Turkey: a Classification Analysis
    (Elsevier Science Inc, 2016) Cinaroğlu, S.; Başer, Onur
    Objectives: The unbalanced distribution of medical technologies and devices between rural and urban areas is a major problem for developing countries including Turkey. After the establishment of Public Hospital Unions (PHUs) in Turkey, legislative changes were made to improve the autonomy of public hospitals. This study utilizes spatial analysis to assess the distribution of medical device use in Turkey using PHUs as a decision making unit. Methods: Data from the PHUs’ statistics year book for the year 2014 was assessed. The total number of PHUs is 89. A Hierarchical cluster analysis was performed to classify PHUs according to the total number of medical devices. The Euclidean distance measure and Wards methods were used in the analysis for classification. Results: Study results show that, in Turkey, PHUs were categorized into two clusters based on the total number of medical devices available. Regarding the spatial distribution of the clusters, the first cluster represents PHUs in rural areas, and the second represents PHUs located in urban areas of Turkey. PHUs representing large cities with high population density were included in one cluster, and all other PHUs were included in the second. Statistical test results indicated that the two clusters differ according to the total number of magnetic resonance imaging (MRI: t= -14.10, p< 0.01), computed tomography (CT) scan (t= -15.75, p< 0.01), mammography (t= -11.40, p< 0.01), ultrasonography (t= -14.62, p< 0.01), and electrocardiography (EKG; t= -12.29, p< 0.01) equipment available. Conclusions: It is advisable for health policy makers and health technology assessment authorities in Turkey to focus on the differences between rural and urban areas of the country when determining the need for medical devices.
  • Conference Object
    Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population
    (2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H.
    ...
  • Conference Object
  • Conference Object
    Demographic and Clinical Characteristics of Patients With Polycythemia Vera (pv) in the Us Veterans Population
    (2016) Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L,; Başer, Onur
    ...
  • Article
    Citation - WoS: 15
    Citation - Scopus: 15
    Economic Outcomes in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone
    (Springer, 2020) Lechpammer, Stanislav; Ramaswamy, Krishnan; Wang, Li; Mardekian, Jack; George, Daniel J.; Sandin, Rickard; Schultz, Neil M.; Başer, Onur; Huang, Ahong
    Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naı¨ve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone). Methods: We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. Results: We identified 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p\0.0001) and PC-related outpatient visits (0.86 vs 1.03; p\0.0001), with corresponding lower all-cause ($2588 vs $3115; p\0.0001) and PC-related ($1356 vs $1775; p\0.0001) PPPM outpatient costs compared with the abiraterone cohort. Allcause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p\0.0001) were significantly lower in the enzalutamide cohort compared with the abiraterone cohort. Conclusions: Enzalutamide-treated men with chemotherapy-naı ¨ve mCRPC had significantly lower resource utilization and healthcare costs compared with abiraterone-treated men. Plain Language Summary: Plain language summary available for this article.
  • Conference Object
  • Article
    Citation - WoS: 26
    Citation - Scopus: 30
    Prevalence of Mastocytosis and Hymenoptera Venom Allergy in the United States
    (Mosby-Elsevier, 2021) Volertas, Sofija; Akın, Cem; Khokhar, Dilawar; Schuler, Charles F; Chen, Lu; Yüce, Huseyin; Montejo, Jenny M; Başer, Onur
    Background : Mastocytosis is a risk factor for hymenoptera venom anaphylaxis (HVA). Current guidelines recommend measuring tryptase in HVA patients and that those with mastocytosis pursue lifelong venom immunotherapy (VIT). Available data on HVA and mastocytosis largely derives from European single-center studies and the prevalence of HVA with and without mastocytosis in the United States (US) is unknown.Objective : We sought to determine the prevalence of HVA and mastocytosis in the US using an insurance claims database and evaluate the impact of mastocytosis on VIT in HVA patients in a US cohort. Methods :The IBM Watson Database, consisting of insurance claims from approximately 27 million US patients in 2018, was queried to identify patients with HVA and/or mastocytosis. Further, a retrospective study of 161 patients undergoing VIT between 2015 – 2018 at the University of Michigan (U-M) was conducted. Results :In the IBM Watson Database, the prevalence of HVA was 167 per 100,000 (0.167%) and the prevalence of mastocytosis 10 per 100,000 (0.010%) overall and 97 per 100,000 (0.097%) among those with HVA. Mastocytosis showed a 9.7-fold increase among HVA patients versus the general population. In the U-M cohort, 2.6% of VIT patients had mastocytosis. Tryptase level did not correlate with venom reaction severity but was higher in patients with systemic VIT reactions. Conclusions :We observed a lower US HVA prevalence than previously reported. Mastocytosis was more common in US HVA patients, though at lower rates than previously reported. In VIT patients there was no correlation between tryptase level and reaction severity. Key words :Tryptasevenom allergyvenom immunotherapyanaphylaxismastocytosismast cell activation syndromemast cell disease Abbreviations Hymenoptera venom allergyHVAUnited StatesUSVenom immunotherapyVITMast Cell DiseaseMCDAmerican Academy of Allergy, Asthma, and Immunology
  • Article
    Network Among Hta Ecosystem
    (Springer Verlag, 2019) Çınaroğlu, Songül; Başer, Onur
    This study intends to examine the main drivers of network relations among health technology assessment (HTA) organizations. Social network analysis was performed to determine the relations among HTA organizations and to visualize the main drivers of such collaboration. The members in HTA organizations such as International Society for Pharmacoeconomics and Outcomes Research, Health Technology Assessment international, International Network of Agencies for Health Technology Assessment, EuroScan, European Network for Health Technology Assessment, HTAsiaLink, and Health Technology Assessment Network for the Americas are said to create networks. Ten different HTA organizations were considered in the analysis, including the Ministry of Health (MoH) organizations, universities, for-profit organizations, and hospitals. The Fruchterman-Reingold algorithm was used to perform networking, and the average clustering coefficient and average path length were examined to measure collaborative performance. The network graph of the HTA ecosystem shows the highest collaborative frequency among HTA organizations, which are the members of MoH organizations, government agencies, universities, and nonprofit organizations. The average path length was 2.21, and the average clustering coefficient was 36.57, indicating an obvious clustering effect. The study results highlight that networking within the HTA ecosystem is driven by government organizations. Boosting the integration of the private sector into the system and creating data-sharing strategies are essential to foster HTA collaboration. Because HTA is shaped by local dynamics and no gold standard exists for HTA implementation, encouraging collaborative efforts is the only way to avoid redundant efforts and make health technologies available for everyone.